We are developing a novel class of therapeutic agents: compounds that release carbon monoxide (CO) under defined conditions. The compounds have been developed following the discovery that CO, like nitric oxide, is a naturally occurring chemical messenger that, in physiological doses, has anti-inflammatory, hypotensive and anti-apoptotic properties and can suppress graft rejection and protect tissues from ischemic damage.
You need to upgrade your Flash Player
This is replaced by the Flash content of the Hemocorm Video.
Welcome to hemoCORM
hemoCORM Ltd is a London based company that is establishing a leading position in an exciting and emerging pharmacological field – the use of carbon monoxide as a therapeutic agent.
News & Events
15 September 2008
CO Based Therapies Take Giant Leap with Merger of Two Leaders in Field
Dispensing metal carbonyls
23 March 2007
Carbon monoxide releasing molecules offer new opportunities for treating disease.
24 January 2007
Several groups of scientists are developing compounds that slowly release carbon monoxide directly into the bloodstream and could be used to treat diseases as diverse as high blood pressure, heart disease and cancer.
01 December 2006
30 November 2006
Accessible site by 